Axumin SOW.pdf

Axumin BPA 4 February 2020

1. Introduction: The 88TH Medical Treatment Facility (MTF) located at Wright–Patterson AFB, OH requires a five (5) year Blanket Purchase Agreement (BPA) for Axumin (fluciclovine F 18) The primary objective of this effort is to allow for the rapid procurement of these solutions to perform necessary examinations.

2. Background: Axumin™ (fluciclovine F 18) injection is indicated for positron emission tomography (PET) imaging in men with suspected prostate cancer recurrence based on elevated blood prostate specific antigen (PSA) levels following prior treatment. Axumin was developed to enable visualization of the increased amino acid transport that occurs in many cancers, including prostate cancer.

3. Delivery Requirement: Vendor will deliver doses of Axumin to the Customer Location FOB destination, and will add any applicable delivery charges to the invoice.

4. Building address: 4881 Sugar Maple Dr.

Bldg. 830, Area A

WPAFB OH 45433-5529

5. Minimum Requirements:

o Item/Description:

Axumin (fluciclovine F 18) injection o Performance Requirements:

Vendor will deliver doses of Axumin to the Customer Location FOB destination, and will add any applicable delivery charges to the invoice.

In the event that the customer is unable to perform a patient scan due to an Axumin dose arriving in an unusable form, the vendor will not invoice customer for the dose or associated additional charges.

o Standards, guidelines or approvals – Must be FDA approved.

STATEMENT OF WORK